acute myeloid leukemia (AML)

Orca prepares to make market plunge after phase 3 win

Orca-T offers “good efficacy and low toxicity,” CEO Ivan Dimov said, noting that the combination of features represents the "holy grail" in the space.

Gabrielle Masson Mar 17, 2025 7:00am

A series of dice with a bag on them illustrating cost cuts

Ryvu loses 30% of staff in focus on ph. 3 blood cancer trials

Feb 25, 2025 10:00am

Apollomics, after giving up on leukemia drug, posts ph. 3 fail

Dec 20, 2024 9:30am

Foghorn drops sole wholly owned clinical asset after AML failure

Dec 16, 2024 7:48am

pay deal hand over cash licensing transaction money

Kyowa Kirin fronts $330M to share rights to Kura's leukemia drug

Nov 21, 2024 9:35am

decision path change of plans arrows business decision

Molecular Partners tweaks AML trial over 'suboptimal exposure'

Aug 27, 2024 10:00am